The ADA's updated clinical practice guideline confirms that comprehensive clinical examinations followed by biopsy remain the most effective methods for detecting and confirming early-stage oral and lip cancers, while recommending against routine use of cytology, light-based tests, vital staining, or salivary adjuncts for screening.
- Clinical exams and biopsy are the only definitive methods to detect and confirm oral cancer; biopsy is essential for diagnosis confirmation.
- The ADA recommends against routine use of commercially available cytology, light-based tests, vital staining, and salivary adjuncts for screening or determining biopsy need.
- This is the ADA's first guideline under its new Living Guideline Program, which updates recommendations as soon as new evidence emerges rather than every three to five years.
Comprehensive clinical examinations followed by biopsy remain the most effective way to detect and confirm early-stage oral and lip cancers, according to an updated clinical practice guideline from the ADA.
The guideline, published online in advance of print in The Journal of the American Dental Association, is the first developed under the ADA's Living Guideline Program, launched in 2025. It updates the association's 2017 guideline on evaluating potentially malignant disorders, including oral cancer.
The American Cancer Society estimates that 60,480 new cases of oral cavity or oropharyngeal cancer will be diagnosed in 2026, with 13,150 deaths resulting from the disease.
"Dental visits can save lives," said Dr. Mark Lingen, the guideline panel chair and professor of pathology at the University of Chicago Medicine. "Oral cancer can be serious, but early detection often leads to better patient outcomes."
Adjuncts not recommended for routine use
The panel generally recommended against routine use of commercially available cytology, light-based, vital staining, or salivary adjuncts. This applies both to deciding whether adults with visible lesions need a biopsy or specialist referral and to screening adults without visible lesions.
Cytology may be offered in limited cases when biopsy is not possible, advisable, or indicated, particularly for concerning lesions. Salivary adjunct tests are recommended only for research settings.
Biopsy remains the only definitive method to confirm a diagnosis of oral potentially malignant disorders and oral and lip squamous cell carcinomas, according to the guideline.
Patient awareness matters
Dr. Alessandro Villa, chief of oral medicine, oral oncology, and dentistry at Herbert Wertheim Cancer Institute and the ADA Council on Scientific Affairs' representative on the panel, emphasized the importance of patient vigilance between visits.
"Do not ignore a sore or lump in your mouth that hasn't healed in two to three weeks," Villa said, adding that patients should alert their dentist or physician, especially if they also experience bleeding, pain, difficulty swallowing, or hoarseness.
Faster updates ahead
Traditional guidelines are typically revised every three to five years. Living guidelines keep the same methodological rigor but are updated as soon as new evidence emerges to reach clinicians and patients more quickly.
The ADA led development with methodologists from the Center for Integrative Global Oral Health at the University of Pennsylvania School of Dental Medicine and a multidisciplinary panel. The ADA Council on Scientific Affairs provided oversight.
"Getting emerging evidence into the hands of clinicians quickly can be the difference between early detection of oral cancer and a late-stage diagnosis," said Olivia Urquhart, associate director of health care guidelines at the Penn center.
Read the full guideline and related resources.
